ClinicalTrials.gg
CompletedNCT01850641Updated Oct 9, 2018Results posted

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

A Phase 3 interventional study of PA21 in Hemodialysis and Hyperphosphatemia, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Enrollment
31st of 36
35 · median 117
Started
2013
with 5 others
Phase 3
23 of 41
3 open now
Registered
21st of 41
by date
Lead sponsor
5 of 41
Kissei Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2013, is one of 23 in phase 3, and was the 21st registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.

03

Conditions studied

  • Hemodialysis
  • Hyperphosphatemia

Browse trials for

Keywords

  • Hemodialysis
  • Hyperphosphatemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving stable maintenance hemodialysis 3 times a week
  • Dialysis patients with hyperphosphatemia

Exclusion criteria

Exclusion Criteria:

  • Patients having history of a pronounced brain / cardiovascular disorder
  • Patients having severe gastrointestinal disorders
  • Patients having severe hepatic disorders
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    PA21

    Drug: PA21

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Time frame: 12 weeks

Secondary outcomes

  1. Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  2. Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  3. Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  4. Serum Ferritin Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  5. TSAT at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  6. Hb Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  7. Constipation Condition

    Time frame: 12 weeks

  8. Satisfaction With Bowel Movement

    Time frame: 12 weeks

07

Results

Posted Oct 9, 2018

Participant flow

Participant flow — Overall Study
MilestonePA21
Started35
Completed30
Not completed5
Withdrew: Physician decision1
Withdrew: Decrease in serum phosphorus1
Withdrew: Decrease in serum calcium2
Withdrew: Increase in serum ferritin1

Outcome measures

PrimaryIncidence of Adverse Events
Time frame:
12 weeks
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsPA21
Incidence of Adverse Events28
SecondarySerum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · mg/dL
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
mg/dLPA21
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)4.89 ± 1.14
SecondaryCorrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · mg/dL
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
mg/dLPA21
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)9.52 ± 0.88
SecondarySerum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · pg/mL
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
pg/mLPA21
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)177.9 ± 146.4
SecondarySerum Ferritin Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Median · ng/mL
Serum Ferritin Concentrations at End of Treatment (Actual Measured Value)
ng/mLPA21
Serum Ferritin Concentrations at End of Treatment (Actual Measured Value)73.8 (38.2 to 183.0)
SecondaryTSAT at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · percentage of TSAT
TSAT at End of Treatment (Actual Measured Value)
percentage of TSATPA21
TSAT at End of Treatment (Actual Measured Value)27.72 ± 8.27
SecondaryHb Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · g/dL
Hb Concentrations at End of Treatment (Actual Measured Value)
g/dLPA21
Hb Concentrations at End of Treatment (Actual Measured Value)11.22 ± 1.19
SecondaryConstipation Condition
Time frame:
12 weeks
Reported as:
Count of participants · Participants
Constipation Condition
ParticipantsPA21
Week 0 — Not at all bothersome15
Week 0 — Bothers me very little14
Week 0 — Somewhat bothersome2
Week 0 — Bothers me quite a lot4
Week 0 — Could not tolerate0
End of treatment — Not at all bothersome26
End of treatment — Bothers me very little5
End of treatment — Somewhat bothersome2
End of treatment — Bothers me quite a lot2
End of treatment — Could not tolerate0
SecondarySatisfaction With Bowel Movement
Time frame:
12 weeks
Reported as:
Count of participants · Participants
Satisfaction With Bowel Movement
ParticipantsPA21
Week 0 — Very much satisfied/Satisfied21
Week 0 — Can say neither8
Week 0 — Very much dissatisfied/Dissatisfied6
End of treatment — Very much satisfied/Satisfied28
End of treatment — Can say neither5
End of treatment — Very much dissatisfied/Dissatisfied2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PA210/35 (0%)1/35 (2.9%)23/35 (65.7%)
Most frequent serious events
Most frequent serious events
EventPA21
Hepatitis acuteHepatobiliary disorders1/35
Most frequent other events
Most frequent other events
EventPA21
DiarrhoeaGastrointestinal disorders14/35
NasopharyngitisInfections and infestations10/35
Dermatitis contactSkin and subcutaneous tissue disorders2/35
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders2/35
Back painMusculoskeletal and connective tissue disorders2/35
WoundInjury, poisoning and procedural complications2/35

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)PA21
Mean63.7 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)PA21
Female14
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PA21
American Indian or Alaska Native0
Asian35
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Dialysis vintage
Dialysis vintage(months)PA21
Mean111.1 ± 87.5
08

Study locations

1 site
  • Multiple Locations, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Dec 2013, 8 months.

Results were first posted in Oct 2018, 4 years 10 months after primary completion.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2013
First posted
May 9, 2013
StartActual
Apr 29, 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 3, 2013
Results first posted
Oct 9, 2018
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01850641
Responsible party
Sponsor
First posted
May 9, 2013
Start date
Apr 29, 2013
Primary completion
Dec 2013
Completion
Dec 3, 2013
Results posted
Oct 9, 2018
Last update
Oct 9, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion